Categories
- Actions
- Copay Accumulators
- Copay Assistance
- COVID-19
- Drug Costs
- Featured
- Federal Issues
- Health Insurance
- Health Policy
- ICER
- Issues
- Letters Submitted
- Letters Supported
- Medicaid
- Medicare
- Medicare Part D
- News
- Op-Ed
- Out of Pocket Costs
- Pharmacy Benefit Managers
- Podcast
- QALY
- State Issues
- Step Therapy
- Uncategorized
- Value Frameworks
Tags
340B
Biden Administration
Cancer
chemo drugs
cms
Copay Accumulators
copay assistance
COVID-19 Vaccine
deferred action
DPC
drug costs
drug discount programs
Drug Importation
Drug Manufacturing
Drug Pricing
drug rebate
Elizabeth Warren
fail first
Health Insurance
hospital bills
HR 3708
hsa
ICER
Imported Drugs
Insurance design
Joe Biden
Medicaid
medicare Part B
medicare part D
Nonmedical Switching
open enrollment
out of
Out of Pocket Costs
Patient Access
Patients Assitance
PBM
pharmacy
pharmacy benefit managers
Preexisting Conditions
Price Transparency
Prior Authorization
QALY
Step Therapy
transparency
Value Framework
Recent Posts
- UnitedHealthcare’s Mid-Year Change in Remicade Coverage a Concern for Stable Patients
- COVID-19 Vaccination: Do States Have a Grip on The Process Yet?
- Season 2 | Episode 3: When Might You Get the COVID-19 Shot?
- New Government, Revised Rules? Seniors and Prescription Drug Cost-Sharing
- S2 | E2: Mystery Hospital Costs